Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

559 ARTÍCULOS , VIENDO DEL 421 AL 435

Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease

Shah AJ, Mohi-Ud-Din R, Sabreen S, Wani TU, Jan R, Javed MN, Mir PA, Mir RH, Masoodi MH.

Curr Mol Pharmacol. 2023;16(3):254-279. doi: 10.2174/1874467215666220903095837.

CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab

Nisenbaum L, Martone R, Chen T, Rajagovindan R, Dent G, Beaver J, Rubel C, Racine A, He P, Harrison K, Dean R, Vandijck M, Haeberlein SB.

Alzheimers Dement. 2023 Aug;19(8):3379-3388. doi: 10.1002/alz.12919. Epub 2023 Feb 16.

Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer's disease and synucleinopathies

Sensi SL, Russo M, Tiraboschi P.

Handb Clin Neurol. 2023;192:187-218. doi: 10.1016/B978-0-323-85538-9.00015-8.

Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications

Gonzalez-Ortiz F, Kac PR, Brum WS, Zetterberg H, Blennow K, Karikari TK.

Mol Neurodegener. 2023 Mar 16;18(1):18. doi: 10.1186/s13024-023-00605-8.

Advances and applications of fluids biomarkers in diagnosis and therapeutic targets of Alzheimer's disease

Xu Y, Jiang H, Zhu B, Cao M, Feng T, Sun Z, Du G, Zhao Z.

CNS Neurosci Ther. 2023 Aug;29(8):2060-2073. doi: 10.1111/cns.14238. Epub 2023 May 5.

Boswellic Acids Improve Clinical Cognitive Scores and Reduce Systemic Inflammation in Patients with Mild to Moderate Alzheimer's Disease

Karima S, Aghamollaii V, Mahmoodi Baram S, Balenci L, Lanctôt KL, Kiss A, Tafakhori A, Mahdavi M, Rajaei S, Shateri S, Yarhoseini A, Mokhtari F, Fotouhi A, Riazi A.

J Alzheimers Dis. 2023;94(1):359-370. doi: 10.3233/JAD-221026.

MRI in the new era of antiamyloid mAbs for the treatment of Alzheimer's disease

Filippi M, Cecchetti G, Agosta F.

Curr Opin Neurol. 2023 Aug 1;36(4):239-244. doi: 10.1097/WCO.0000000000001177. Epub 2023 Jun 23.

A review of neuroimaging-based data-driven approach for Alzheimer's disease heterogeneity analysis

Liu L, Sun S, Kang W, Wu S, Lin L.

Rev Neurosci. 2023 Jul 10;35(2):121-139. doi: 10.1515/revneuro-2023-0033. Print 2024 Feb 26.

Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis

Jeremic D, Navarro-López JD, Jiménez-Díaz L.

Ageing Res Rev. 2023 Sep;90:102012. doi: 10.1016/j.arr.2023.102012. Epub 2023 Jul 7.

The Synergistic Potential of Combining PD-1/PD-L1 Immune Checkpoint Inhibitors with NOD2 Agonists in Alzheimer's Disease Treatment

Ghareghani M, Rivest S.

Int J Mol Sci. 2023 Jun 30;24(13):10905. doi: 10.3390/ijms241310905.

Obstructive sleep apnea and dementia: A role to play?

Kinugawa K.

Rev Neurol (Paris). 2023 Oct;179(7):793-803. doi: 10.1016/j.neurol.2023.08.006. Epub 2023 Aug 24.

Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification

Cummings JL, Osse AML, Kinney JW.

Drugs. 2023 Oct;83(15):1387-1408. doi: 10.1007/s40265-023-01938-w. Epub 2023 Sep 20.

Accelerating Alzheimer's therapeutic development: The past and future of clinical trials

Boxer AL, Sperling R.

Cell. 2023 Oct 26;186(22):4757-4772. doi: 10.1016/j.cell.2023.09.023. Epub 2023 Oct 16.

The Critical Role of Biomarkers for Drug Development Targeting the Biology of Aging

Owen M, Bose N, Nisenbaum L, Partrick KA, Fillit HM.

J Prev Alzheimers Dis. 2023;10(4):729-742. doi: 10.14283/jpad.2023.111.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias